FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0283								
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Cline Darren S</u>				<u>PI</u>	2. Issuer Name and Ticker or Trading Symbol PLIANT THERAPEUTICS, INC. [PLRX]] (Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Image: Person Ima			vner	
(Last)	(Fi	rst)				3. Date of Earliest Transaction (Month/Day/Year) 06/13/2024							Officer below)	(give title	Other (s below)	pecify
C/O PLIANT THERAPEUTICS, INC. 260 LITTLEFIELD AVENUE				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person					
(Street) SOUTH FRANCI		A	94080		R	ule 1	10b5-	1(c)	Transac	ction Ind	ication		Form f Persor		han One Repo	ting
(City)	(S	tate)	(Zip)						cate that a trar defense condi					n or written pla	n that is intended	I to
		Tab	le I - Non	-Deriv	vativ	e Sec	curities	s Ac	quired, Di	sposed o	f, or Be	neficiall	y Owned			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,		Date,	3. Transaction Code (Instr) 8)					es For ally (D) Following (I) (orm: Direct)) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
				Code V			Amount	(A) or (D) Price		Reported Transact (Instr. 3 a	ion(s)		Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	ate,	4. Transactio Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Common Stock (Right to Buy)	\$13.06	06/13/2024			Α		26,764		(1)	06/13/2034	Common Stock	26,764	\$0	26,764	D	

Explanation of Responses:

1. 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 13th, 2024 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 13, 2024 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Remarks:

/s/ Mike Ouimette, attorney-in-

fact

06/17/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.